Skip to main content
. Author manuscript; available in PMC: 2024 Jun 5.
Published in final edited form as: Circulation. 2024 Jun 3;149(23):1786–1788. doi: 10.1161/CIRCULATIONAHA.123.066916

Figure 1. The impact of CYP2C19 pharmacogenetics on mavacamten pharmacokinetics.

Figure 1

The figure depicts the variation in CYP2C19 enzymatic activity, the impact on mavacamten pharmacokinetics, and the alteration in the plasma concentration of mavacamten due to genetic variants. The prevalence of metabolizer status of global populations for CYP2C19 is adapted from the Clinical Pharmacogenetics Implementation Consortium. PK, pharmacokinetics.